Related references
Note: Only part of the references are listed.Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
Krishna Babu Duggirala et al.
BIOMOLECULES & THERAPEUTICS (2022)
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
Jie He et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Geun Taek Lee et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
Xiaojuan Qu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile
Chaowei Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
Hao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Xin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations
Jaebong Jang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects
Yiqing Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
Camille Mehlman et al.
LUNG CANCER (2019)
Targeted protein degradation: expanding the toolbox
Matthieu Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Tobias Grabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Sainan An et al.
EBIOMEDICINE (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami et al.
COMMUNICATIONS BIOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Ken Uchibori et al.
NATURE COMMUNICATIONS (2017)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
